Compare VINP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | STTK |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.4M | 652.4M |
| IPO Year | 2020 | 2020 |
| Metric | VINP | STTK |
|---|---|---|
| Price | $9.03 | $5.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $14.41 | ★ $15.40 |
| AVG Volume (30 Days) | 114.8K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | ★ 6.77% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $16.59 | N/A |
| Revenue Next Year | $14.07 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.91 | $1.72 |
| 52 Week High | $13.61 | $8.33 |
| Indicator | VINP | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 47.91 |
| Support Level | N/A | $5.19 |
| Resistance Level | $10.17 | $7.66 |
| Average True Range (ATR) | 0.50 | 0.37 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 5.54 | 60.69 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.